NEWS AND MEDIA
Recent News
Purdue Pharma Urges Accuracy in Communications on Abuse-Deterrent Formulations of Opioids
STAMFORD, Conn. – September 24, 2018 – Marcelo E. Bigal MD, Ph.D. Chief Medical Officer, Purdue Pharma L.P., issued the following statement today: The nation’s opioid crisis is a significant and urgent public health challenge, and Purdue Pharma is deeply concerned…
Purdue Pharma L.P. and Geisinger Present Interim Analysis from Wearable Health Technology Clinical Trial at PAINWeek® 2018 Annual Conference
Purdue Pharma L.P. and Geisinger Present Interim Analysis fromWearable Health Technology Clinical Trial at PAINWeek® 2018 Annual ConferenceResults Show Successful Uptake of Technology and Increased Patient-Provider Communication STAMFORD, Conn., and DANVILLE, Pa. –…
Purdue Pharma L.P. to Present Data from Three Research Studies at PAINWeek® 2018 Annual Conference
Purdue Pharma L.P. to Present Data from Three Research Studies atPAINWeek® 2018 Annual ConferenceStudies Underscore Company’s Ongoing Commitment to Working Collaboratively onMeaningful Solutions to Address the Opioid Crisis STAMFORD, Conn., September 6, 2018 – Purdue…
Purdue Pharma L.P. to Fund Harm Reduction Therapeutics, Inc.’s Work to Develop Inexpensive, Over-the-Counter, Life-Saving Naloxone in the United States
STAMFORD, Conn. and PITTSBURGH, Penn., September 5, 2018 – Purdue Pharma L.P. (Purdue) and Harm Reduction Therapeutics, Inc. today announced that Purdue is providing a $3.42 million grant to Harm Reduction Therapeutics to advance the development of its low-cost,…
Prescription Drug Safety Curriculum Increased Student Knowledge by 49 Percent in its Inaugural Academic Year
Purdue Expands Established Commitment to Include a Statewide Education Program in Collaboration with EVERFI and Connecticut Prevention Network for the 2018-2019 Academic Year STAMFORD, Conn., August 15, 2018 — Purdue Pharma L.P. today announced that, through its…
Purdue Pharma L.P. Issues Statement on Opioid Promotion
STAMFORD, Conn. – February 9, 2018 – Purdue Pharma L.P. issued the following statement today: We have restructured and significantly reduced our commercial operation and our sales representatives will no longer promote opioids to prescribers. Going forward, questions…
Purdue Pharma L.P. Awards Grants to Further Research on the Assessment of Chronic Pain
Research includes study of Virtual Reality technology as potential tool in chronic pain assessment STAMFORD, Conn. – January 31, 2018 – Purdue Pharma L.P. today announced the funding of three grants for investigator-initiated research on developing clinically relevant…